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Functional connectivityFibromyalgia is a chronic pain syndrome characterized by widespread pain, fatigue, and memory and mood
disturbances. Despite advances in our understanding of the underlying pathophysiology, treatment is often chal-
lenging. New research indicates that changes in functional connectivity between brain regions, as can be mea-
sured by magnetic resonance imaging (fcMRI) of the resting state, may underlie the pathogenesis of this and
other chronic pain states. As such, this parameter may be able to be used to monitor changes in brain function
associated with pharmacological treatment, and might also be able to predict treatment response.
Weperformed a resting state fcMRI trial using a randomized, placebo-controlled, cross-over design to investigate
mechanisms of action ofmilnacipran (MLN), a selective serotonin and norepinephrine reuptake inhibitor (SNRI),
in ﬁbromyalgia patients. Our aimwas to identify functional connectivity patterns at baseline that would differen-
tially predict treatment response to MLN as compared to placebo. Since preclinical studies of MLN suggest that
this medication works by augmenting antinociceptive processes, we speciﬁcally investigated brain regions
known to be involved in pain inhibition.
15 ﬁbromyalgia patients completed the study, consisting of 6 weeks of drug and placebo intake (order
counterbalanced) with an interspersed 2 week wash out period. As a main ﬁnding we report that reductions
in clinical pain scores during MLN were associated with decreased functional connectivity between
pro-nociceptive regions and antinociceptive pain regions at baseline, speciﬁcally between the rostral part of
the anterior cingulate cortex (ACC) and the insular cortex (IC), as well as between the periaqueductal gray
(PAG) and the IC: patients with lower preexisting functional connectivity had the greatest reduction in clinical
pain. This pattern was not observed for the placebo period. However a more robust placebo response was
associated with lower baseline functional connectivity between the ACC and the dorsolateral prefrontal cortex.
This study indicates that ACC–IC connectivity might play a role in the mechanism of action of MLN, and perhaps
more importantly fcMRI might be a useful tool to predict pharmacological treatment response.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Fibromyalgia is a chronic pain syndrome of unknown origin, esti-
mated to affect 2–5% in all populations studied (Raspe, 1992; Wolfe
et al., 1995; Assumpcao et al., 2009; Dhir et al., 2009). Fibromyalgiacortex; BPI, brief pain inventory;
; DLPFC, dorsolateral prefrontal
, functional connectivitymagnet-
rror; MCC, mid-cingulate cortex;
inephrine; PAG, periaqueductal
sory testing; rs-fc, resting state
epinephrine reuptake inhibitor;
netic stimulation.
l.de (T. Schmidt-Wilcke).
. This is an open access article underis characterized by widespread pain, fatigue, poor sleep, and
dyscognition (Wolfe et al., 2010) and is often also associated with
mood disorders such as depressive episodes and anxiety. Although
the underlying pathophysiology is not entirely understood, ﬁbromy-
algia has been associated with augmented central nervous system
(CNS) processing of nociceptive stimuli using both quantitative sen-
sory testing (QST) and functional neuroimaging. (Gracely et al.,
2002; Desmeules et al., 2003; Petzke et al., 2003; Smith et al.,
2008). In this context the notion of dysfunctional endogenous pain
inhibition has been proposed to play a pivotal role in the genesis of
chronic widespread pain. This is supported by studies demonstrating
impaired or absent conditioned pain modulation (CPM) in these pa-
tients (Lautenbacher and Rollman, 1997; Vierck et al., 2001; Julien
et al., 2005; Chalaye et al., 2014).
In recent years, functional (Gracely et al., 2002; Giesecke et al.,
2004; Jensen et al., 2012) and structural (Kuchinad et al., 2007;the CC BY-NC-ND license
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have shed some light on possible central mechanisms that might play a
role in the genesis of chronic pain in ﬁbromyalgia. One such approach is
the investigation of ﬂuctuations in blood oxygenation level dependent
(BOLD) signals at rest, termed resting state functional connectivity
(rs-fc). This method identiﬁes and assesses the interaction between
disparate cortical regions and networks. Only recently have changes in
rs-fc been demonstrated in ﬁbromyalgia, such as a hyper-connectivity
between the default mode network (DMN), a constellation of brain re-
gions involved in self-referential thought, and the insular cortex (IC), a
brain region known to play a pivotal role in pain perception (Napadow
et al., 2010). Interestingly this hyper-connectivity may be a marker for
chronic pain intensity as two independent trials have shown that de-
creases in connectivity between the DMN and IC following treatment
were associated with reductions in clinical pain (Napadow et al., 2012;
Harris et al., 2013).
Treatment of ﬁbromyalgia in terms of a clinically relevant reduction
in widespread pain is often challenging and both pharmacological and
non-pharmacological approaches (Bernardy et al., 2013). To date,
three drugs have been approved by the U.S. Food and Drug Administra-
tion for the treatment of pain in ﬁbromyalgia: pregabalin, a compound
that binds to the α2δ subunit of a voltage dependent presynaptic calci-
um channel, and two selective serotonin (5-HT) and norepinephrine
(NE) reuptake inhibitors, milnacipran (MLN) and duloxetine
(Goldenberg et al., 2010; Schmidt-Wilcke and Clauw, 2010; Schmidt-
Wilcke and Clauw, 2011). Other drugs, such as tricyclic compounds
(TCA, e.g. amitryptiline), viewed as non-selective 5-HT and NE reuptake
inhibitors, have also repeatedly been shown to be efﬁcacious in the
treatment of ﬁbromyalgia and are frequently used in pharmacological
treatment regimens. Theway 5-HT andNE reuptake inhibitors act to re-
duce pain is still a matter of debate as spinal, subcortical, and cortical
mechanisms have all been proposed. However the overall effect of any
of these individual treatments has been modest (Häuser et al., 2013).
Moreover a key limitation in the treatment of ﬁbromyalgia, and chronic
pain in general, is that there are no reliable tools to guide treatment as-
signment for individual patients. As such, clinical routine largely relies
on trial and error.
Recently our group has shown that chemical and functional imag-
ing in ﬁbromyalgia can be used to predict treatment response to
pregabalin in ﬁbromyalgia (Harris et al., 2013). Here we sought to
identify rs-fc patterns that might predict treatment response in ﬁ-
bromyalgia to the selective 5-HT and NE reuptake inhibitor MLN.
Since preclinical studies have indicated that dual reuptake inhibitors
are thought to have a favorable effect on endogenous pain inhibition
which is believed to be dysfunctional in ﬁbromyalgia (Lautenbacher
and Rollman, 1997; Julien et al., 2005), we speciﬁcally focused on rs-
fc to brain regions involved in antinociception and pain modulation
such as: the periaqueductal gray (PAG), the rostral part of the ante-
rior cingulate cortex (ACC), the dorsolateral prefrontal cortex
(DLPFC) and the amygdala.
2. Material and methods
2.1. Subjects
We investigated 23 female patients diagnosed with ﬁbromyalgia. In-
clusion criteria were: (1) meeting 1990 American College of Rheumatol-
ogy criteria for FM with chronic widespread pain for at least 6 months;
(2) 18–70 years of age; (3) non-lactating and non-pregnant; (4) right
handed; (5) score between 40 and 90 mm (inclusive) on a 100 mm
pain Visual Analogue Scale (VAS); (6) willing to withdraw from CNS-
active therapiesmarketed as antidepressants (monoamine oxidase inhib-
itors, tricyclics, tetracyclics, selective serotonin reuptake inhibitors,
norepinephrine reuptake inhibitors, and SNRIs); (7) willing to withdraw
from stimulant medications such as those used to treat attention
deﬁcit disorder and attention deﬁcit hyperactivity disorder (e.g. mixedamphetamine salts, methylphenidate, dextroamphetamine) or fatigue
associated sleep apnea or shift work (e.g. modaﬁnil); (8) willing to with-
draw from anorectic agents such as diethylpropion, sibutramine, and
phentermine; and (9) if currently taking pregabalin and/or gabapentin,
to remain on a stable dosage throughout the duration of the study.
Major exclusion criteria were: (1) signiﬁcant risk of suicide; (2) medical
conditions including cardiac diseases, glaucoma, autoimmune disease,
systemic infections (e.g. human immunodeﬁciency virus, hepatitis),
active cancer, pulmonary disease or dysfunction, unstable endocrine dis-
ease (must be stable at least 3 months prior to study enrollment), unsta-
ble diabetes, unstable thyroid disease; (3) pregnant or lactating; (4) any
other severe, acute, or chronic medical or psychiatric conditions that
could increase risk or interfere with trial results; (5) body mass index
greater than 36; (6) treatment with any experimental agent, including
MLN, within 30 days before screening; and (7) contraindications with
MRI procedures.
All study participants gave written informed consent. The study
protocol and informed consent documents were approved by the Uni-
versity of Michigan Institutional Review Board (Ann Arbor, Michigan)
and Forest Laboratories (New York, NY). All clinical data were veriﬁed
for accuracy and the database was locked before analysis. All imaging
data were stored, validated, analyzed, and assessed for quality at the
University of Michigan independent of Forest personnel. Patient demo-
graphics, medications, and identiﬁcation of inclusion for analysis are
listed in Table 1.
2.2. Treatment
All patients were randomized in a double-blind, two-period cross-
over study of MLN versus placebo (Fig. 1). Potential participants
underwent an initial visit, prior to the ﬁrst neuroimaging session,
wherein they were evaluated for study criteria. After meeting inclu-
sion/exclusion criteria, consenting patients were randomized to either
MLN ﬁrst or placebo ﬁrst for Period 1, and which followed 1–4 week
washout period to withdraw from all excluded medications that could
interfere with efﬁcacy and neuroimaging measures. This washout peri-
od included a 1-week single-blind placebo run-in period to reduce the
possibility of placebo effects during the ﬁrst double-blind treatment pe-
riod. Following the placebo run-in period, all participants underwent
their ﬁrst neuroimaging scan (pretreatment for Period 1) which in-
volved functional connectivity magnetic resonance imaging (fcMRI).
Following this initial scan, subjects randomized to receive MLN in the
ﬁrst period, underwent dose escalation of MLN up to 200 mg/day over
the course of 2 weeks, with a maintained ﬁxed dose for 4 weeks, at
which time an identical post-treatment fcMRI session was conducted.
Those subjects randomized to placebo for Period 1 tookmatching place-
bo pills over the course of 6 weeks before undergoing an identical post-
treatment fcMRI session. Results from post-treatment scans will be pre-
sented elsewhere. All participants then entered a 1 week taper and
2 weeks of a placebo washout, during which time a placebo sugar pill
was consumed daily. Once the washout period was completed, all pa-
tients crossed over to the other study drug for Period 2 (i.e. those who
had MLN for Period 1 received placebo for Period 2 and vice versa.).
Neuroimaging sessions for Period 2 were identical to those in Period 1.
Placebodata included in all analyses came fromeither Period 1 or Period
2 (depending on treatment order), andwere included for all subjects re-
gardless of treatment order. All subjects were informed that theywould
be dosed with MLN or placebo at various times throughout the study,
but were not told when they were transferred from one treatment to
the other. All investigators and research team members were blinded
to study drug and placebo timing.
2.3. Pain assessment and analysis
We assessed treatment response for both clinical pain as well as
evoked experimental pain in all participants prior to and following
Table 1
Patients included in analysis, demographics, and medications/supplements.
Patient Age Race BMI Medications and supplements
1 54 Caucasian 33 Tramadol, Vitamin D, Fish Oil
2 26 Caucasian 36 Lyrica, Vitamin D, Metaformin
3 30 Caucasian 31 Metronidazole, Benadryl, Motrin
4 42 Caucasian 27 Ibuprofen, Sudafed
5 53 Caucasian 33 Di-nox, Anacin, Aleve, Ibuprofen , Vitamin D, Vitamin B Complex, Pednisone, Mobic, Mucinex, Ventolin, Airborne
6 36 African
American
37 Amlodipine Besylate, Lisinopril-HCTZ, Aleve
7 40 Caucasian 24 Nuvaring, Ibuprofen, Skelaxin, Vicodin, Tylenol, Quasense
8 36 Caucasian 21 Synthroid, Tylenol, Acetaminophen, Motrin, Ibuprofen
9 39 Caucasian 21 Nasonex, digestive enzyme, Calcium/Magnesium/Vitamin D
10 50 Caucasian 29 Lisinopril/hctz, Amoxicillin
11 30 Caucasian 28 Xanax, Cataphlam, Aleve
12 40 Caucasian 23 Motrin, Mega Dose Multivitamin/Mineral Complex, Probiotic
13 53 African
American
26 B-complex 50, Vitamin D, Coq 10, Maca Herb, Omega 3 Fish oil, Hyurunate Acid, Motrin, Excedrin
14 27 Caucasian 32 Levothyroxine, Vitron-C, Singulair,Albuterol Sulfate, Vicodin, Multivitamin, hycosamine, Folic Acid, B-6, Rogaine, Zyrtec, Magnesium
citrate, Cyclobenzabrine, Maxalt, Tylenol, Cortizone shots, Kelp, Vitamin D, Cephalexin
15 55 Caucasian 35 Avapro Norvasc, Aldactazyde, Detrol LA, Lyrica, Synthroid, Taclonex, Diprolene Gel, Aspirin, Vitamin D, Iron, Calcium, multivitamin, Tylenol,
Motrin, Minocycline, methotrexate, Methotrexate
BMI = Body Mass Index.
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Brief Pain Inventory (BPI) which captures both pain severity (BPI Sev)
and interference due to pain (BPI Int) (Cleeland and Ryan, 1994) mea-
sured over the course of the previous week. Changes in these compo-
nents (post minus pre) were used as measures of treatment response
for clinical pain. Changes in pain both following MLN and placebo
were assessed in SPSS, version 20, by performing paired t-tests. Fur-
ther, we speciﬁcally investigated whether changes following MLN
treatment differed signiﬁcantly from changes following placebo
treatment by performing paired samples t-tests of the change scores
for all behavioral measures, also in SPSS, version 20. When assessing
for responders compared to non-responders to a treatment period,
we deﬁned a patient to be a responder if she had ≥30% improve-
ment for a behavioral measure after a treatment period. Patients
with b30% improvement after a treatment period were categorized
as non-responders.
Evoked experimental pain data was also collected in and outside the
MRI scanner before and after each treatment period. Pressure-pain was
administered to the left thumbnail with three distinct conditions using
the Multi-modal Automated Sensory Testing (MAST) system (HarteFig. 1.Overview of study design. Subjects underwent a baseline visit where theywere assessed
ized into themilnacipran or placebo treatment arm. Both clinical pain and experimental pain w
began a 1 week placebo run-in period. Patients that entered themilnacipran period ﬁrst were d
dose for 4 weeks. Subjects randomized to placebo for the ﬁrst period took matching placebo pil
neuroimaging session. Following the completion of period one, all subjects underwent a 1week
to the other study drug for the second period. MRI = magnetic resonance imaging; tx = treatet al., 2013): 1) an equal pressure condition of 1.5 kg/cm2, 2) the
amount of pressure required to elicit Pain50 on the 0–100 NRS, and
3) a faint touch rest condition. Both behavioral and BOLD fMRI response
data will be analyzed and reported in a subsequent manuscript.
2.4. Resting state functional connectivity magnetic resonance imaging
(fcMRI) acquisition and analysis
2.4.1. Data acquisition and pre-processing
In this investigation we were primarily interested in identifying
baseline neuroimaging parameters that could predict changes in clinical
and evoked pain speciﬁcally following treatment with MLN. Resting
state fMRI data were acquired using a T2*-weighted spiral sequence
(TR = 2.0 s, TE = 30 ms, FA = 90°, matrix size 64 × 64 with 43 slices,
FOV = 20 cm and 3.12 × 3.12 × 3 mm voxels), using a 3 Tesla General
Electric, Signa scanner 9.0, VH3 with 16 rod birdcage transmit–receive
radio frequency coil. During the 6 min resting state fMRI acquisition
period (180 scans), subjects were asked to remain awake with their
eyes open and to stare at a motionless cross presented on the screen.
Minimal cognitive tasks such as staring at a cross are thought not tofor study criteria. Those that met inclusion/exclusion criteria were consented and random-
ere assessed at each neuroimaging visit. Prior to their ﬁrst neuroimaging session, subjects
ose escalated over 2 weeks to a stable dose of 200mg/day, andmaintained this ﬁxed daily
ls for 6 weeks. After the 6 total weeks for this period, subjects underwent a post-treatment
taper and 2weeks of placebowashout. After thewashout period, participants crossed over
ment.
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of the resting state scan were discarded from the data set and not ana-
lyzed in order to avoid equilibration effects. A T-1 weighted structural
gradient echo data set (TR 1400 ms, TE 1.8 ms, ﬂip angle 15°, FOV
256 × 256, yielding 124 sagittal slices with a deﬁned voxel size of
1 × 1 × 1.2 mm) was also acquired for each subject.
Data were pre-processed and analyzed using FSL (http://www.
fmrib.ox.ac.uk/fsl) and Statistical Parametric Mapping software pack-
ages (SPM, version 8, Functional Imaging Laboratories, London, UK), as
well as the functional connectivity toolbox Conn (Cognitive and Affec-
tive Neuroscience Laboratory, Massachusetts Institute of Technology,
Cambridge, USA) running under Matlab 7.5b (Mathworks, Sherborn,
MA, USA). Upon collection of the functional data, cardiorespiratory arti-
facts were corrected for using the RETROICOR (Hu et al., 1995; Pfeuffer
et al., 2002) algorithm in FSL. Pre-processing steps includedmotion cor-
rection (realignment to theﬁrst image of the time series), normalization
to the standard SPM–EPI template (generating 2 × 2 × 2mm resolution
images) and smoothing (convolution with an 8 mm FWHM Gaussian
Kernel). Subject head motion was assessed by evaluating three transla-
tions and three rotations for each scan. Translational thresholds were
set to ±2 mm, while rotational thresholds were limited to ±1°. A
subject was to be excluded from the analysis if head motion exceeded
either of the thresholds in one of the six dimensions.
As SNRIs are thought to augment antinociceptive mechanisms, we
were particularly interested in rs-fc to brain regions known to be
involved in the descending antinociceptive/pain modulatory system.
The following regions were chosen based on the current literature
suggesting involvement in antinociception/pain modulation (Bingel,
2010): three seeds covering the rostral ACC, the ventral (vACC), pre-
genual (pgACC) and subgenual (sgACC) regions, and bilateral seeds in:Fig. 2. Region of interest seeds included in the rs-fc analysis. Fig. 2 displays a priori seed
regions included in the resting state functional connectivity analysis. Three anterior cingu-
late cortex spheres with radii of 5mm included the ventral ACC (x=−3, y= 32, z= 19),
the pre-genual ACC (x= 0, y= 40, z= 0), subgenual ACC (x=−3, y= 32, z= –8), two
periaqueductal gray spherical seedswith 4mm radii (left: x= 6, y=−26, z= –14; right:
x =−6, y =−26, z = –14), four dorsolateral prefrontal cortex spherical seeds of 5 mm
radii (left medial-inferior: x = −30, y = 15, z = 29; left lateral-superior: x = −40,
y = 12, z = 44; right medial-inferior: x = 30, y = 15, z = 29; right lateral-superior:
x = 40, y = 12, z = 44), and two amygdala spherical seeds of 5 mm radii (left:
x = −32, y = 2, z = –16; right: x = 32, y = 2, z = 16).the dorsolateral prefrontal cortex (DLPFC), the amygdala, and the
periaqueductal gray (PAG); seed regions were created using the SPM
extension tool Marsbar. All seed regions were created as spheres. For
further information including size and location, refer to Fig. 2.
Within the Conn toolbox, seed regions3 time-series were extracted;
whitematter, cerebrospinal ﬂuid, and realignment parameterswere en-
tered into the analysis as covariates of no interest. A band-pass ﬁlter
(frequency window: 0.01–0.1 Hz) was applied, thus removing linear
drift artifacts and high frequency noise. First level analyses were per-
formed correlating seed region signal with voxel signal throughout
the whole brain, thereby creating seed region to voxel connectivity
maps (one map per seed per individual).
2.4.2. Association of rs-fc with pain reduction (group level analysis)
For group analyses we focused on pre- MLN rs-fc as a predictor of
subsequent change in pain resulting from the drug. Results from these
regions were then compared to placebo. Our primary approach was to
enter pre-treatment connectivity maps in amultiple regression analysis
with changes in pain (post-MLNminus pre-MLN) in SPM. Results were
deemed signiﬁcant using a family wise error (FWE) cluster corrected
threshold of p b 0.05. Within a priori brain regions, including: the IC,
posterior cingulate cortex (PCC), precuneus, inferior parietal lobule
(IPL), andDLPFC, a small volume correction using a spherewith a radius
of 5 mm was performed, and results were deemed signiﬁcant at a
(FWE) cluster level corrected threshold of p b 0.05. These regions had
been selected as a priori regions becausewewere speciﬁcally interested
in rs-fc changes to regions known to be involved in pain processing,
which allowed for small volume correction analysis based on previously
published results. Signiﬁcant results were then extracted and entered
into SPSS, version 20, to assess for outliers. To determine if these results
were speciﬁc toMLN, identical analyseswere performed for the placebo
period, using the signiﬁcant regions identiﬁed as predicting response to
MLN. In order to rule out chance differences by treatment period at
baseline, we compared the MLN and placebo correlations for the two
cross-over periods separately (i.e. those that had MLN ﬁrst and those
that had placebo ﬁrst). Correlations were performed in SPSS, version
20, and results were found to be signiﬁcant at p b 0.05.
Finally, we sought to incorporate multiple functional connectivity
measures in a regression analysis to explore for collinearity amongst
our rs-fc outcomes and to further improve prediction of treatment re-
sponse, while simultaneously controlling for pre-treatment pain levels
(Harris et al., 2013). To this end a multiple linear regression model
was created with pre-treatment pain measures and rs-fc correlation
values serving as independent variables and post-treatment pain as
the dependent variable. A model was ﬁrst constructed with each rs-fc
measure individually and then in combination (when multiple rs-fc
values predicted the same pain outcome) by way of forward selection.
Signiﬁcance was set at p b 0.05.
3. Results
Twenty-three female ﬁbromyalgia patients were enrolled in the
study. Eight were excluded from the analysis for the following reasons:
six withdrew prior to completing all neuroimaging sessions (two pre-
maturely stopped taking MLN, two had side effects from the drug that
prevented participation in the trial, and two terminated due to personal
reasons), and two additional participants were excluded because they
did not reach the pre-speciﬁed dose of MLN before imaging. The drop-
out rate due to adverse events of themedication was 9% (2 of 23 partic-
ipants). Thus ﬁfteen subjects (mean age: 40.7 ± 10.2) were included in
the present analysis. Of these ﬁfteen subjects, thirteen were Caucasian,
while two were African American. The mean Body Mass Index of this
sample was 29.1 ± 5.3. All subjects were conﬁrmed to be right-
handed. Additional details including medications and supplements for
all patients are contained in Table 1.
Table 2
Behavioral data.
MLN Period PBO Period
Subject Age Resp pre BPI Sev pre BPI Int post BPI Sev post BPI Int Resp pre BPI Sev pre BPI Int post BPI Sev post BPI Int
FM01 36 ΦѰ 4.8 1.9 2.8 1.0 Φ 3.0 1.0 1.5 1.3
FM02 40 7.8 8.1 6.8 9.0 6.3 7.9 5.0 8.4
FM03 42 ΦѰ 4.3 0.9 1.0 0.4 ΦѰ 6.3 2.7 3.8 0.6
FM04 54 7.0 6.9 7.0 5.7 7.3 6.6 7.0 6.6
FM05 40 3.3 2.0 2.3 2.4 Ѱ 3.0 4.7 4.5 2.0
FM06 26 4.0 6.3 6.8 5.7 4.0 4.3 5.0 6.7
FM07 55 ΦѰ 7.0 6.6 4.3 4.4 7.3 7.9 6.8 6.3
FM08 30 8.5 8.0 8.3 8.6 6.8 3.0 6.3 5.0
FM09 39 5.5 6.3 6.3 5.1 ΦѰ 5.8 6.3 1.0 0.7
FM10 53 Φ 4.3 1.1 1.5 3.3 1.3 4.3 7.0 3.7
FM11 50 ΦѰ 5.3 6.0 3.3 2.3 3.5 3.0 5.0 5.1
FM12 53 Ѱ 7.0 5.9 4.8 3.4 6.3 5.0 5.0 4.3
FM13 27 Ѱ 8.0 9.4 6.0 6.0 7.3 9.0 8.0 8.6
FM14 30 Ѱ 5.5 6.9 6.5 3.3 5.8 2.1 5.5 2.0
FM15 36 4.5 4.1 6.0 3.6 Ѱ 4.5 5.1 4.3 3.1
Table 2 includes behavioral data from all 15 patients thatwere analyzed in this study. Both pre- and post-treatment values are included from theMLN andplaceboperiods. A responder to a
treatment periodwas deﬁned as a 30% improvement from the pre-scan time point to the post-scan time point.Φ= responder for BPI Sev,Ѱ= responder for BPI Int. FM= ﬁbromyalgia,
BPI Sev = Brief Pain Inventory – Severity component score, BPI Int = Brief Pain Inventory – Interference component score, MLN =milnacipran, PBO = placebo.
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Multiple dimensions of clinical pain were found to show signiﬁcant
decreases and trends towards decreased pain after treatment with
MLN but not placebo (BPI Sev change; MLN: mean = −0.88 ± 1.8,
p = 0.076; PBO: mean = −0.17 ± 2.3, p = 0.78; BPI Int change;
MLN: mean =−1.1 ± 1.7, p= 0.03; PBO: mean =−0.56 ± 2.1, p=
0.31). When comparing the effects of treatment periods to each other,
no signiﬁcant differences between MLN and placebo treatment were
observed (BPI Sev: p=0.39, BPI Int: p=0.50). According to our a priori
deﬁnition of responders: 5 of 15 patients (33%)were responders toMLN
and 3 of 15 patients (20%)were responders to placebo treatment for BPI
Sev, whereas 7 of 15 patients (47%) were responders to MLN treatment
and 4 of 15 patients (27%)were responders to placebo for BPI Int scores
(Table 2).
3.2. Pre-treatment rs-fc outcomes predict response to MLN treatment and
placebo
We found strong associations between baseline rs-fc values (i.e. rs-fc
correlation values between our pre-speciﬁed antinociceptive brain re-
gions and other brain regions involved in pain processing/modulation)
and changes in clinical and experimental painmeasures after treatment
periods (Table 3). A signiﬁcant association was found between rs-fc of
the right PAG seed and the right mid-IC, and subsequent reduction in
clinical pain severity (BPI Sev; MLN: r = 0.885, p b 0.001; placebo:
r = –0.216, p = 0.440; Table 3 and Fig. 3A). In this region, less rs-fcTable 3
Connectivity prediction of behavioral response results.
Pre-tx connectivity (seed to region) Size (voxels) Coordinates (MNI)
x y
R PAG–R midIC 21 34 −2
R DLPFC–L IPL 152 −40 −44
L amyg–PCC/precuneus 232 −4 −64
pgACC–R IC 133 36 −6
pgACC–L DLPFC 95 −52 12
Table 3 displays signiﬁcant results from the pre-treatment scan connectivity prediction analyse
placebo period statistics are displayed, with results found to be signiﬁcant in bold. Statistics fr
cingulate cortex, pgACC = pregenual anterior cingulate cortex, BPI Int = Short Form of the Br
Severity score; DLPFC = dorsolateral prefrontal cortex, IC = insular cortex, IPL = inferior par
Pre-tx = pre-treatment, R = right.activitywas associatedwith greater reductions in clinical pain following
MLN treatment but not placebo. We also observed a signiﬁcant associa-
tion between connectivity of the right DLPFC and the left IPL, and chang-
es in BPI Sev during MLN but not placebo (MLN: r= 0.873, p b 0.001;
placebo: r = 0.030, p = 0.917; Table 3 and Fig. 3B). With respect to
the limbic system, connectivity between the left amygdala and the
precuneus/posterior cingulate cortex (PCC) was found to have a nega-
tive correlation with change in BPI Sev in response to MLN but not pla-
cebo (MLN: r = –0.916, p b 0.001; placebo: r = –0.389, p = 0.152;
Table 3 and Fig. 3C). For these regions greater rs-fc was associated
with greater reductions in clinical pain following MLN but not placebo.
Low levels of connectivity between the pgACC and the right posterior
IC were found to be associated with a greater reduction in clinical pain
interference (BPI Int) following MLN but not placebo (MLN: r= 0.900,
p b 0.001; placebo: r= 0.082, p= 0.771; Table 3 and Fig. 4A).
For placebo, lower levels of connectivity between the pgACC and the
left DLPFCwere associatedwith greater pain reduction, i.e. patientswith
less connectivity of these two structures at baseline would showed a
greater response in clinical pain interference (BPI Int) during placebo
treatment (placebo: r = 0.869, p b 0.001, MLN: r = –0.050, p =
0.859; Table 3, Fig. 5).
When assessing each treatment period separately, it was found that
order of treatment (MLNor placebo administered in theﬁrst period) did
not impact the results.
Two linear regression models predicting changes in BPI Sev during
the MLN period were constructed. The ﬁrst model for this measure
included pre-MLN BPI Sev values (Adjusted R Square = 0.34, p =Milnacipran period Placebo period
r value p value r value p value
z
BPI Sev
16 0.885 b0.001 −0.216 0.440
46 0.873 b0.001 0.030 0.917
10 −0.916 b0.001 −0.389 0.152
BPI Int
10 0.900 b0.001 0.082 0.771
34 -0.050 0.859 0.869 b0.001
s for clinical and experimental pain changes to treatment by period. Both milnacipran and
om the placebo period are provided to demonstrate no signiﬁcant effect. ACC = anterior
ief Pain Inventory–Interference score, BPI Sev = Short Form of the Brief Pain Inventory–
ietal lobule, L = left, MNI = Montreal Neurological Institute, PAG = periaqueductal gray,
Fig. 3. Pre-MLN resting state functional connectivity predicts pain severity reductions in response to MLN treatment. Fig. 3 displays pre-milnacipran (MLN) treatment connectivity as a
predictor for clinical response toMLN. Results displayed contain seed-to-target connectivity (seed regions displayed on the left) and plots of signiﬁcant regressions for theMLN treatment
arm (A. Mid-IC; B. DLPFC; C. PCC/precuneus), and corresponding statistics for the placebo treatment period. Orange dots represent patients that had PBO treatment ﬁrst, and MLN treat-
ment second.Green dots represent patients that receivedMLN treatmentﬁrst, and PBO second. ACC=anterior cingulate cortex, amyg=amygdala, BPI Sev=Brief Pain Inventory severity
scores, DLPFC=dorsolateral prefrontal cortex, IC= insular cortex, IPL= inferior parietal lobule, L= left,MLN=milnacipran, PAG=periaqueductal gray, PBO=placebo, PCC=posterior
cingulate cortex, pre-cun = precuneus, R = right.
257T. Schmidt-Wilcke et al. / NeuroImage: Clinical 6 (2014) 252–2610.014), right PAG to right mid-IC connectivity (Adjusted R Square =
0.50, p b 0.001), and right DLPFC to left IPL connectivity (Adjusted
R Square = 0.10, p = 0.001) as independent predictors and ex-
plained 94% of the variance of post-MLN pain severity. A second
model explained 95% of the variance of post-MLN BPI Sev scores
which included pre-MLN BPI Sev values (Adjusted R Square =Fig. 4. Pre-MLN resting state functional connectivity predicts decrease in pain interference redu
nectivity as a predictor for pain response to MLN. Results displayed contain seed-to-target con
treatment arm and corresponding statistics for the placebo treatment period. ACC = anterior
IPL = inferior parietal lobule, L = left, MLN =milnacipran, PBO= placebo, R = right.0.34, p = 0.014), right PAG to right mid-IC connectivity (Adjusted
R Square = 0.51, p b 0.001), and left amygdala to right PCC/
precuneus (Adjusted R Square = 0.10, p b 0.001) as independent
predictors (Table 4).
One additional model was created to explain pain interference. In
the ﬁrst model, independent predictors including pre-MLN BPI Intction in response toMLN treatment. Fig. 4 displays pre-milnacipran (MLN) treatment con-
nectivity (seed regions displayed on left) and plots of signiﬁcant regressions for the MLN
cingulate cortex, BPI Int = Brief Pain Inventory interference scores, IC = insular cortex,
Fig. 5. Pre-placebo resting state functional connectivity predicts clinical pain reduction in response to placebo treatment. Fig. 5 displays pre-placebo (PBO) treatment connectivity as a pre-
dictor for response to PBO pills. Results displayed contain seed-to-target connectivity (seed regions displayed on left) and plots of signiﬁcant regressions for the PBO treatment arm, and
corresponding statistics for theMLN treatment period. ACC= anterior cingulate cortex, BPI Int=Brief Pain Inventory interference scores, DLPFC=dorsolateral prefrontal cortex, L= left,
MLN =milnacipran, PBO= placebo, R = right.
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between the pgACC and right posterior IC (Adjusted R Square = 0.32,
p b 0.001) explained 90% of the variance of post-MLN pain interference
(Table 4).
4. Discussion
We investigated rs-fc of cortical and subcortical structures involved in
pain modulation to determine parameters that would predict treatment
response to treatment with MLN in patients with ﬁbromyalgia. Impor-
tantly, we ﬁnd that ACC–IC as well as PAG–IC connectivity at baseline
were predictive of treatment response: patients that displayed lower
pgACC–IC connectivity or PAG–IC connectivity, respectively, showed
greater reductions in clinical pain following MLN treatment. Other rs-fc
measures were also predictive of clinical response to MLN treatment,
such as DLPFC–IPL and amygdala–precuneus/PCC connectivity, while
less pgACC–DLPFC connectivity was predictive of placebo response.
We hypothesize that a subgroup of ﬁbromyalgia patients with poor con-
nectivity between pro- and antinociceptive brain regions, proﬁts from
SNRI treatment, and this pattern reﬂects a dysfunctional endogenous
antinociceptive system or can be viewed as a biomarker thereof.
A dysfunctional endogenous antinociceptive system has been sug-
gested to be a contributor to the genesis of pain in FM (LautenbacherTable 4
Pre-treatment connectivity outcomes predict subsequent clinical pain response to milnacipran
Dependent variable Predictor
Clinical pain
Post-MLN BPI sev
Clinical pain: pre-MLN BPI Sev
R PAG to R mid-IC connectivity correlations
R DLPFC to L IPL connectivity correlations
Clinical pain
Post-MLN BPI sev
Clinical pain: pre-MLN BPI Sev
R PAG to R mid-IC connectivity correlations
L amygdala to PCC/precuneus connectivity correlations
Clinical pain
Post-MLN BPI Int
Clinical pain: pre-MLN BPI Int
pgACC to R posterior IC connectivity correlations
Table 4 contains three separate linear regressionmodels, two for post-milnacipran BPI Sev, and
sures and pre-milnacipran connectivity correlations as predictors. The models explain 90–95%
vACC=ventral anterior cingulate cortex, amyg=amygdala, BPI Int=Short Formof the Brief Pa
score, DLPFC=dorsolateral prefrontal cortex, IC= insular cortex, IPL= inferior parietal lobule,
R= right, S.E.= standard error. The R Square FullModel columndisplays overall explained vari
and then the contribution of the addition of subsequent predictors are displayed which total thand Rollman, 1997; Vierck et al., 2001; Julien et al., 2005). There is in-
deed evidence that CNS levels of the two key neurotransmitters within
the antinociceptive system, 5-HT andNE, are lowered in FMas indicated
by decreased levels of the corresponding metabolites in the cerebrospi-
nal ﬂuid (Russell et al., 1992; Legangneux et al., 2001). SNRIs are
thought to support the antinociceptive system by increasing synaptic
5-HT and NE levels that in turn reduce the nociceptive input to the
brain. SNRIs are well characterized with respect to their molecular
mechanisms, targeting presynaptic transporter proteins (e.g. SERT),
thereby raising synaptic 5-HT and NE levels. However, since 5-HT and
NE can bind to different receptor subtypes with different effects and
concentrations at different CNS sites, the overall effect of 5-HT and NE
reuptake inhibition is highly complex. In the context of pain and pain
modulation however predominantly spinal mechanisms are discussed
to account for the analgesic effects (Yoshimura and Furue, 2006;
Burnham and Dickenson, 2013). For 5-HT this is via binding to 5-HT1A,
5-HT1B and 5-HT1D receptors that lead to pre- and post-synaptic hyper-
polarization of pain transmitting neurons. Furthermore 5-HT increases
inhibitory transmitter release (e.g. GABA) from interneurons via 5-
HT3 and possibly 5-HT2. NE, on the other hand is thought to act via pre-
synaptic α1 receptors leading to a suppression of glutamate release
from both Aδ and C afferent ﬁbers, aswell as viaα2 receptors increasing
inhibitory transmitter release from interneurons. Importantly these.
Standardized β S.E. unstandardized p value R Square full model
0.94
0.62 0.30 0.014 0.34
0.70 1.64 b0.001 0.84
0.42 0.85 0.001 0.94
0.95
0.62 0.30 0.014 0.34
0.70 1.64 b0.001 0.85
−0.46 1.26 b0.001 0.95
0.90
0.78 0.16 0.001 0.58
0.69 1.37 b0.001 0.90
one for post-milnacipran BPI Int. Thesemodelswere built using pre-milnacipran painmea-
of the variance in post-milnacipran pain. pgACC = pregenual anterior cingulate cortex,
in Inventory–Interference score, BPI Sev=Short Formof theBrief Pain Inventory–Severity
L= left,MLN=milnacipran, PAG=periaqueductal gray, PCC=posterior cingulate cortex,
ance in italics for eachdependent variable. Below this value, the variance for each predictor,
e overall variance.
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conditions, such as diabetic neuropathy (Boyle et al., 2012), osteoarthri-
tis (Chappell et al., 2009) as well as ﬁbromyalgia (Goldenberg et al.,
2010; Häuser et al., 2012b) and are not thought to be speciﬁc to one par-
ticular pain condition. Interestingly for ﬁbromyalgia a recently pub-
lished study investigating spinal effects of MLN via the assessment of
the nociceptive ﬂexion reﬂex (R III), came to the conclusion that MLN
must also have supraspinal effects, based on the observation that
there was a dose dependent analgesic effect in the absence of an MLN
associated modulation of the nociceptive ﬂexion reﬂex (Matthey et al.,
2013). The only study to date that we are aware of to directly test
whether diminished descending analgesic activity is predictive of treat-
ment response with these classes of drugs is a study by Yarnitsky and
colleagues showing that those neuropathic pain patients with impaired
descending activity at baseline on QST were more likely to respond to
duloxetine (Yarnitsky et al., 2012).
Our choice of seed regions for the rs-fc connectivity analyses was
based on the current literature highlighting the role of some key struc-
tures in pain inhibition and pain modulation, i.e. the PAG, the rostral
ACC, the DLPFC and the amygdala (Petrovic et al., 2002; Wager et al.,
2004; Bingel et al., 2007). Our strongest ﬁndings, which are also well
in line with our a priori hypotheses is, that ACC–IC connectivity and
PAG–IC connectivity were predictive of treatment response. Within
the endogenous antinociceptive system the PAG plays a central role co-
ordinating via the rostroventromedial medulla (RVM) (Moreau and
Fields, 1986; Heinricher et al., 2009) activity in the descending 5-HT
and NE pathways that project to the spinal cord to decrease nociceptive
routing from the periphery. The PAG itself receives input from both spi-
nal nociceptive neurons a variety of cortical structures. It has been hy-
pothesized that there are two cortical systems that mediate cortical
top down modulation; one pathway involves descending input from
the rostral ACC (to the prefrontal cortex and then to the PAG); a second
pathway arrives at the PAG from the IC via the amygdala (Schweinhardt
and Bushnell, 2010). That said, it needs to be acknowledged that most
evidence stems from animal research (Fields, 2004) and that the precise
mapping of these pathways in humans is currently unknown. However,
the notion of the rostral ACC–PAG connectivity (Hardy and Leichnetz,
1981), interacting in this regard, has recently been supported by both
functional (Petrovic et al., 2002; Bingel, 2010; Kong et al., 2010) and
structural (Stein et al., 2012) imaging studies. The interaction of the ros-
tral ACC and IC in antinociception and pain modulation on the other
hand remains to be further elucidated. Both structures are part of a cor-
tical opioidergic network (Petrovic et al., 2002), as such the rostral ACC
might exert direct “antinociceptive activity” on the IC cortex, or both
structures modulate the PAG either interactively or independently,
and rs-fc reﬂects coordinated activity of the two systems.
When looking at resting state networks the bilateral IC togetherwith
the dorsal ACC, MCC and supplementary motor area make up the so
called salience network and connectivitywithin this network inﬂuences
perceptual decisions on pain. The vACC, pgACC and sgACC as such are
not part of the salience network, but rather belong to the executive con-
trol network (vACC) and theDMN(pgACC and sgACC) (Beckmann et al.,
2005). As such one would not expect highly correlated BOLD activity
between the rostral ACC and IC even in healthy subjects; intriguingly a
negative correlation in resting state activity between these two regions
is predictive of MLN response. In a recently performed study we found
an increased rostral ACC–IC rs-fc in young patients with temporoman-
dibular disorder that we interpreted as an early compensatory mecha-
nism in a group of young patients developing a chronic pain condition
(Ichesco et al., 2012). Given that rostral ACC–IC connectivity reﬂects
synchronized antinociceptive “effort”, it is tempting to hypothesize that
a break down in this mechanism is then associated with further pain
chroniﬁcation, based on an increasingly dysfunctional antinociceptive
system.
The other rs-fc patterns that predicted response to MLN treatment
were the right DLPFC and the left IPL as well as amygdala and theposterior cingulate cortex. These connections are less well established
in pain and antinociception research. The IPL as well as the posterior
cingulate cortex are both part of theDMN. The role of theDMN in chron-
ic pain is beginning to be investigated, as in our previous work in ﬁbro-
myalgia suggesting that IC connectivity to the DMN is associated with
increased pain (Napadow et al., 2010). Interestingly in this present
work, we show that lowered DMN connectivity to antinociceptive re-
gions, such as the DLPFC, are predictive of response to MLN. Other
DMN regions such as the PCC have also been highlighted as being
involved in pain in other functional and structural imaging studies
(Erpelding et al., 2012).
Another interesting ﬁnding of our study is that pgACC–left DLPFC
connectivity predicted response to placebo treatment. Fibromyalgia pa-
tients with a lower pgACC–left DLPFC connectivity showed greater pain
reductionswhile undergoingplacebo treatment. The placebo effect inﬁ-
bromyalgia patients has recently been investigated in meta-analyses
based on randomized, placebo-controlled trials. In these studies,
18–30% of patients have been shown to be placebo responders; as
such the magnitude of placebo responders in drug trials of ﬁbromyalgia
is similar to that seen in other chronic pain conditions (Häuser et al.,
2011; Häuser et al., 2012a). The neuralmechanisms underlying the clin-
ical observation that cognitive factors such as beliefs and expectations
can modulate pain perception have been investigated using various
brain imaging methods (Petrovic et al., 2002; Bingel, 2010), mostly
using short term interventions. The role of the DLPFC cortex in placebo
research has been underlined by both fMRI studies (Wager et al., 2004;
Wager et al., 2011) as well as transcranial magnetic stimulation (TMS)
studies describing a signiﬁcant impairment of placebo analgesia associ-
ated with TMS induced functional lesions of the left DLPFC
(Krummenacher et al., 2010). As such the DLPFC is viewed as key region
for initiating placebo related changes in pain perception, the implemen-
tation of which then requires the interaction of other cortical and sub-
cortical brain regions, such as the rostral ACC and the PAG. While
increases in the rostral ACC activity and ACC–PAG connectivity during
placebo analgesia are most likely to be mediated by opioidergic trans-
mission (Petrovic et al., 2002), less is known about the neural correlates
of ACC–DLPFC connectivity. However, our data not only support the no-
tion of ACC–DLPFC playing a key role in placebo analgesia, they also ex-
tend it to a clinical setting, where baseline rs-fc predicts placebo effects
visible 6 weeks after treatment initiation.4.1. Individualized medicine
Despite the signiﬁcant progress that has been made in under-
standing the pathophysiology of ﬁbromyalgia, these advances have
not yet been translated into pharmacological treatment. It is gener-
ally thought that the underlying pathophysiology of ﬁbromyalgia is
heterogeneous leading to a similar phenotype of chronic wide-
spread pain, with only a subgroup of patients with diminished syn-
aptic 5-HT and NE levels responding to drugs that augment this
activity. Despite our small sample size the rates of both drug and
placebo responders are well in line with larger, randomized studies.
Consistent with this idea, the effect of any one of the United States
Food and Drug Administration3s approved drugs examined in isola-
tion is modest with a 30% improvement in pain occurring in only
30–40% of patients (Häuser et al., 2012b), which is also the case in
other chronic pain states; NSAIDs and opioids for example have
modest efﬁcacy in conditions such as osteoarthritis or chronic low
back pain (Clauw, 2010). This stresses the need to develop tools
that predict treatment response, in order to then design individually
tailored therapies (Woolf, 2010). Only very recently have studies indicat-
ed that brain imagingmight be suited to perform such predictions (Harris
et al., 2013; Maarrawi et al., 2013). Resting state fMRI might be a particu-
larly interesting tool, as it is easy and safe to perform with only little
demands on patients3 cognition and cooperation.
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There are some limitations to our study that need to be ad-
dressed. First of all our study is based on a rather small study sam-
ple, i.e. our ﬁndings might not be representative of the larger
ﬁbromyalgia population and may only apply to a subgroup of ﬁbro-
myalgia patients. Also while our drop-out rates, as well as treatment
response to MLN and placebo, were comparable to those seen in
larger randomized, placebo-controlled trials, our results need to be
reproduced in a larger study sample.
As rs-fc analyses allow no assumptions on causality, or on the direct-
edness of inﬂuence, it is conceivable that connectivity between two re-
gions could be driven by a third region, not identiﬁed in the analysis.
Furthermore there is no necessity for a direct causal relationship be-
tween brain connectivity patterns identiﬁed in this study and clinical re-
sponse. Dual reuptake inhibitors are likely to act ﬁrst and foremost on
the spinal level (in the context of pain inhibition), and the connectivity
measures of forebrain structures might thus relate only indirectly to the
site of action. In this scenario connectivity measures would need to be
viewed as surrogate markers, however this would not detract from
their potential clinical usefulness.
Finally, there are four SNRIs used in clinical practice, including
venlafaxine, desvenlafaxine, duloxetine and MLN. MLN blocks 5-HT
and NE reuptake to an equal extent whereas greater selectivity at
5-HT sites has been described for venlafaxine and duloxetine. In this
regard it is uncertain whether our results can be generalized to other
SNRIs or even TCAs. Besides conﬁrmation by studies with larger sample
sizes further research is needed to extent our ﬁndings to other SNRI and
non-selective reuptake inhibitors (e.g. TCAs.).4.3. Conclusion and outlook
Overall we were able to show that rs-fc patterns of brain structures
involved in antinociception and pain modulation might be useful pa-
rameters for the prediction of treatment response to the SNRIMLN in ﬁ-
bromyalgia patients. As in clinical practice only a subset of patients
respond to pharmacological treatment, such approaches might turn
out useful tools to identify subgroups of patients likely to respond to
one or the other approach moving towards an individualized medicine.
Further research is needed to both conﬁrm and extend our ﬁndings.Acknowledgment
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